|Nombre||Título||Pagar||Ejecutado||Año de nacimiento|
|Mr. Stephane Bancel||CEO & Director||4.97M||392.58M||1973|
|Dr. Stephen Hoge M.D.||Pres||2.41M||56.52M||1976|
|Mr. James M. Mock||Chief Financial Officer||1.49M||N/D||1977|
|Ms. Arpa Garay||Chief Commercial Officer||2.67M||N/D||1979|
|Dr. Jerh Collins Ph.D.||Chief Technical Operations & Quality Officer||N/D||N/D||1966|
|Dr. Melissa J. Moore Ph.D.||Chief Scientific Officer & Member of Scientific Advisory Board||N/D||N/D||N/D|
|Mr. Brad Miller||Chief Information Officer||N/D||N/D||1973|
|Ms. Lavina Talukdar CFA||Sr. VP & Head of Investor Relations||N/D||N/D||N/D|
|Ms. Shannon Thyme Klinger||Chief Legal Officer & Corp. Sec.||N/D||N/D||1971|
|Colleen Hussey||Sr. Director of Corp. Communications||N/D||N/D||N/D|
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
La calificación ISS Governance QuickScore de Moderna, Inc. a partir del 1 de septiembre de 2023 es 10. Las puntuaciones principales son Auditoría: 8; Junta: 9; Derechos del accionista: 10; Compensación: 9.